



**ESSEX BIO-TECHNOLOGY LIMITED**  
**億勝生物科技有限公司**

**Press Release**

**100% INCREASED IN PROFIT TO HK\$13.6 MILLION**  
**TURNOVER INCREASED 19.9%**

**ESSEX BIO-TECHNOLOGY LIMITED RECORDED YET ANOTHER**  
**STERLING RESULTS IN THIRD QUARTER 2005**

Hong Kong, 11 November 2005 - - ESSEX BIO-TECHNOLOGY LIMITED (“Essex” or the “Group” - Stock Code: 8151) today announced an unaudited profit attributable to shareholders of approximately HK\$13.6 million for the nine months ended 30 September 2005, a significant increase of approximately 100%, as compared to the approximately HK\$6.8 million of the same period of last year.

Turnover increased by 19.9% to approximately HK\$32.4 million. The increase is mainly attributable to the sustaining growth in sales of the Group’s flagship biopharmaceutical products, Beifuji and Beifushu.

As a result, overall gross profit for the period ended 30 September 2005 increased to approximately HK\$28.6 million as compared to approximately HK\$23.7 million of the same period of last year.

Distribution and selling expenses increased to approximately HK\$17.8 million for the period ended 30 September 2005 when compared to approximately HK\$15 million in the corresponding previous period. The increase was mainly attributable to the increase of sales volume during the period under review, increase of marketing and promotional activities and increase of sales commission.

Administration expenses slightly increased to approximately HK\$6.7 million for the period ended 30 September 2005 as compared to approximately HK\$6.2 million of the same period of last year.

The Group improved significantly its cash on hand to approximately HK\$35.7 million as compared to approximately HK\$22.6 million in last year.

Essex Chairman Patrick Ngiam said: “We are very pleased that the Group recorded yet another profitable quarter. The Group expects continued growth in forth quarter of FY05.”

“With the strong cash on hand, we will seek investments to strategically expand the Group’s business for enhancing shareholders’ value.”

***About Essex Bio-Technology Limited:***

Essex Bio-Technology Limited (“Essex”) was listed on the Growth Enterprise Market (GEM) of The Stock Exchange of Hong Kong Limited on 27 June 2001. Essex specializes in biopharmaceutical drug development based on recombinant DNA technology. It was principally engaged in the manufacture and sale of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds and the research and development of biopharmaceutical products for the treatment of duodenal ulcers and nervous system damages and diseases, as well as other ophthalmic pharmaceutical projects.

The Group currently has two commercialised biopharmaceutical products, namely Beifuji in liquid form, lyophilised powder form and gel form and Beifushu in eye-drop form for the treatment and healing of acute and chronic surface wounds and corneal wounds respectively.

***For more information, please contact:***

***Essex Bio-Technology Limited***

Email : [essex@essexbio.com](mailto:essex@essexbio.com)

Tel : (852) 2587-7838

**Summary of key information:**

	For the nine months ended 30 September	
	2005	2004
	HK\$'m	HK\$'m
Turnover	32.4	27
Gross profit		
- in HK\$'m	28.6	23.7
- in %	88.4%	87.9%
Net Profit	13.6	6.8
Earnings per share		
- basic	HK2.45cents	HK1.23cents
- diluted	HK2.45cents	HK1.23cents
Dividend	Nil	Nil
Cash and bank balances	35.7	22.6
Bank borrowings	Nil	Nil

- End -